Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

Squitieri, Ferdinando; Di Pardo, Alba; Favellato, Mariagrazia; Amico, Enrico; Maglione, Vittorio; Frati, Luigi

doi:10.1111/jcmm.12604

Title: Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

Journal Article · Mon Jun 22 00:00:00 EDT 2015 · Journal of Cellular and Molecular Medicine

DOI:https://doi.org/10.1111/jcmm.12604· OSTI ID:1224661

Squitieri, Ferdinando ^[1]; Di Pardo, Alba ^[1]; Favellato, Mariagrazia ^[1]; Amico, Enrico ^[1]; Maglione, Vittorio ^[1]; Frati, Luigi ^[1]

IRCCS Neuromed Pozzilli Italy

Abstract Huntington disease ( HD ) is a neurodegenerative disorder for which new treatments are urgently needed. Pridopidine is a new dopaminergic stabilizer, recently developed for the treatment of motor symptoms associated with HD . The therapeutic effect of pridopidine in patients with HD has been determined in two double‐blind randomized clinical trials, however, whether pridopidine exerts neuroprotection remains to be addressed. The main goal of this study was to define the potential neuroprotective effect of pridopidine, in HD in vivo and in vitro models, thus providing evidence that might support a potential disease‐modifying action of the drug and possibly clarifying other aspects of pridopidine mode‐of‐action. Our data corroborated the hypothesis of neuroprotective action of pridopidine in HD experimental models. Administration of pridopidine protected cells from apoptosis, and resulted in highly improved motor performance in R6/2 mice. The anti‐apoptotic effect observed in the in vitro system highlighted neuroprotective properties of the drug, and advanced the idea of sigma‐1‐receptor as an additional molecular target implicated in the mechanism of action of pridopidine. Coherent with protective effects, pridopidine‐mediated beneficial effects in R6/2 mice were associated with an increased expression of pro‐survival and neurostimulatory molecules, such as brain derived neurotrophic factor and DARPP 32, and with a reduction in the size of mHtt aggregates in striatal tissues. Taken together, these findings support the theory of pridopidine as molecule with disease‐modifying properties in HD and advance the idea of a valuable therapeutic strategy for effectively treating the disease.

View Journal Article

Cite

Export

Save

Sponsoring Organization:: USDOE

OSTI ID:: 1224661

Alternate ID(s):: OSTI ID: 1345705

Journal Information:: Journal of Cellular and Molecular Medicine, Journal Name: Journal of Cellular and Molecular Medicine Vol. 19 Journal Issue: 11; ISSN 1582-1838

Publisher:: Wiley-BlackwellCopyright Statement

Country of Publication:: Country unknown/Code not available

Language:: English

Citation Metrics:

Cited by: 52 works

Citation information provided by
Web of Science

References (37)

Differences in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912 Tadori, Yoshihiro; Kitagawa, Hisashi; Forbes, Robert A. European Journal of Pharmacology, Vol. 574, Issue 2-3 https://doi.org/10.1016/j.ejphar.2007.07.031	journal	November 2007
Neurochemical Alterations in Huntington'S Chorea: a Study of Post-Mortem Brain Tissue Spokes, E. G. S. Brain, Vol. 103, Issue 1 https://doi.org/10.1093/brain/103.1.179	journal	January 1980
FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease Di Pardo, Alba; Amico, Enrico; Favellato, Mariagrazia Human Molecular Genetics, Vol. 23, Issue 9 https://doi.org/10.1093/hmg/ddt615	journal	December 2013
Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice Di Pardo, A.; Maglione, V.; Alpaugh, M. Proceedings of the National Academy of Sciences, Vol. 109, Issue 9 https://doi.org/10.1073/pnas.1114502109	journal	February 2012
Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington’s disease Jahanshahi, A.; Vlamings, R.; van Roon-Mom, W. M. C. Neuroscience, Vol. 238 https://doi.org/10.1016/j.neuroscience.2013.01.071	journal	May 2013
Altered Dopamine and Serotonin Metabolism in Motorically Asymptomatic R6/2 Mice Mochel, Fanny; Durant, Brandon; Durr, Alexandra PLoS ONE, Vol. 6, Issue 3 https://doi.org/10.1371/journal.pone.0018336	journal	March 2011
Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice Crook, Z. R.; Housman, D. E. Proceedings of the National Academy of Sciences, Vol. 109, Issue 19 https://doi.org/10.1073/pnas.1204542109	journal	April 2012
Dopamine and Glutamate in Huntington's Disease: A Balancing Act: Dopamine-Glutamate Balance in Huntington's Disease André, Véronique M.; Cepeda, Carlos; Levine, Michael S. CNS Neuroscience & Therapeutics, Vol. 16, Issue 3 https://doi.org/10.1111/j.1755-5949.2010.00134.x	journal	May 2010
Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival Hayashi, Teruo; Su, Tsung-Ping Cell, Vol. 131, Issue 3 https://doi.org/10.1016/j.cell.2007.08.036	journal	November 2007
In vivo pharmacology of the dopaminergic stabilizer pridopidine Ponten, Henrik; Kullingsjö, Johan; Lagerkvist, Sören European Journal of Pharmacology, Vol. 644, Issue 1-3 https://doi.org/10.1016/j.ejphar.2010.07.023	journal	October 2010
The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea Huot, P.; Levesque, M.; Parent, A. Brain, Vol. 130, Issue 1 https://doi.org/10.1093/brain/awl332	journal	November 2006
The dopaminergic stabilizer, (−)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins Ruiz, C.; Casarejos, M. J.; Rubio, I. Brain Research, Vol. 1459 https://doi.org/10.1016/j.brainres.2012.04.021	journal	June 2012
Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labeling Hellewell, Susan B.; Bruce, Ashley; Feinstein, Glen European Journal of Pharmacology: Molecular Pharmacology, Vol. 268, Issue 1 https://doi.org/10.1016/0922-4106(94)90115-5	journal	June 1994
The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition Nilsson, Marie; Carlsson, Arvid; Markinhuhta, Katarina Rydén Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, Issue 4 https://doi.org/10.1016/j.pnpbp.2004.05.004	journal	July 2004
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial de Yebenes, Justo Garcia; Landwehrmeyer, Bernhard; Squitieri, Ferdinando The Lancet Neurology, Vol. 10, Issue 12 https://doi.org/10.1016/S1474-4422(11)70233-2	journal	December 2011
The Physiology, Signaling, and Pharmacology of Dopamine Receptors Beaulieu, Jean-Martin; Gainetdinov, Raul R. Pharmacological Reviews, Vol. 63, Issue 1 https://doi.org/10.1124/pr.110.002642	journal	February 2011
Huntingtin Aggregate-Associated Axonal Degeneration is an Early Pathological Event in Huntington's Disease Mice Li, He; Li, Shi-Hua; Yu, Zhao-Xue The Journal of Neuroscience, Vol. 21, Issue 21 https://doi.org/10.1523/JNEUROSCI.21-21-08473.2001	journal	November 2001
The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor Sahlholm, K.; Århem, P.; Fuxe, K. Molecular Psychiatry, Vol. 18, Issue 1 https://doi.org/10.1038/mp.2012.3	journal	February 2012
Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology Armstrong, M. J.; Miyasaki, J. M. Neurology, Vol. 79, Issue 6 https://doi.org/10.1212/WNL.0b013e318263c443	journal	August 2012
Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway Hyrskyluoto, A.; Pulli, I.; Törnqvist, K. Cell Death & Disease, Vol. 4, Issue 5 https://doi.org/10.1038/cddis.2013.170	journal	May 2013
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders Hayashi, Teruo; Tsai, Shang-Yi; Mori, Tomohisa Expert Opinion on Therapeutic Targets, Vol. 15, Issue 5 https://doi.org/10.1517/14728222.2011.560837	journal	February 2011
Poster 19: Validation of the Modified Motor Score (mMS): A Subscale of the Unified Huntington's Disease Rating Scale (UHDRS) Motor Score Waters, S.; Tedroff, J.; Kieburtz, K. Neurotherapeutics, Vol. 7, Issue 1 https://doi.org/10.1016/j.nurt.2009.10.003	journal	January 2010
Is DARPP-32 a potential therapeutic target? Reis, Helton J.; Rosa, Daniela VF; Guimarães, Melissa M. Expert Opinion on Therapeutic Targets, Vol. 11, Issue 12 https://doi.org/10.1517/14728222.11.12.1649	journal	November 2007
A dopaminergic deficit hypothesis of schizophrenia: the path to discovery Carlsson, Arvid; Carlsson, Maria L. Dialogues in Clinical Neuroscience, Vol. 8, Issue 1, p. 137-142 https://doi.org/10.31887/DCNS.2006.8.1/acarlsson	journal	March 2006
Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease Lundin, Anders; Dietrichs, Espen; Haghighi, Sara Clinical Neuropharmacology, Vol. 33, Issue 5 https://doi.org/10.1097/WNF.0b013e3181ebb285	journal	January 2010
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Macdonald, M. Cell, Vol. 72, Issue 6 https://doi.org/10.1016/0092-8674(93)90585-E	journal	March 1993
Mini Review Binder, Devin K.; Scharfman, Helen E. Growth Factors, Vol. 22, Issue 3 https://doi.org/10.1080/08977190410001723308	journal	January 2004
A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease Movement Disorders, Vol. 28, Issue 10, p. 1407-1415 https://doi.org/10.1002/mds.25362	journal	February 2013
Chemical Pathology of Huntington's Disease Bird, E. D. Annual Review of Pharmacology and Toxicology, Vol. 20, Issue 1 https://doi.org/10.1146/annurev.pa.20.040180.002533	journal	April 1980
Impaired Ganglioside Metabolism in Huntington's Disease and Neuroprotective Role of GM1 Maglione, V.; Marchi, P.; Di Pardo, A. Journal of Neuroscience, Vol. 30, Issue 11 https://doi.org/10.1523/JNEUROSCI.6348-09.2010	journal	March 2010
Inotropic action of σ receptor ligands in isolated cardiac myocytes from adult rats Novakova, Marie; Ela, Catherine; Barg, Jacob European Journal of Pharmacology, Vol. 286, Issue 1 https://doi.org/10.1016/0014-2999(95)00424-J	journal	November 1995
Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline: Treatment of Chorea in HD Reilmann, Ralf Movement Disorders, Vol. 28, Issue 8 https://doi.org/10.1002/mds.25500	journal	May 2013
Role of brain-derived neurotrophic factor in Huntington's disease Zuccato, C.; Cattaneo, E. Progress in Neurobiology, Vol. 81, Issue 5-6 https://doi.org/10.1016/j.pneurobio.2007.01.003	journal	April 2007
Cortical and subcortical lesions impair skilled walking in the ladder rung walking test: a new task to evaluate fore- and hindlimb stepping, placing, and co-ordination Metz, Gerlinde A.; Whishaw, Ian Q. Journal of Neuroscience Methods, Vol. 115, Issue 2 https://doi.org/10.1016/S0165-0270(02)00012-2	journal	April 2002
One-year safety and tolerability profile of pridopidine in patients with Huntington disease Squitieri, F.; Landwehrmeyer, B.; Reilmann, R. Neurology, Vol. 80, Issue 12 https://doi.org/10.1212/WNL.0b013e3182886965	journal	February 2013
Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders Sánchez, Ivelisse; Mahlke, Christian; Yuan, Junying Nature, Vol. 421, Issue 6921 https://doi.org/10.1038/nature01301	journal	January 2003
The Dopamine Stabilizers ( S )-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D ₂ Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat Natesan, Sridhar; Svensson, Kjell A.; Reckless, Greg E. Journal of Pharmacology and Experimental Therapeutics, Vol. 318, Issue 2 https://doi.org/10.1124/jpet.106.102905	journal	April 2006

Similar Records

XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent

Journal Article · Mon Apr 09 00:00:00 EDT 2018 · PLoS ONE · OSTI ID:1224661

Polyzos, Aris A.; Wood, Nigel I.; Williams, Paul; +3 more

Inhibition of Drp1 hyperactivation reduces neuropathology and behavioral deficits in zQ175 knock-in mouse model of Huntington's disease

Journal Article · Sat Dec 15 00:00:00 EST 2018 · Biochemical and Biophysical Research Communications · OSTI ID:1224661

Zhao, Yuanyuan; Sun, Xiaoyan; Qi, Xin

Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells

Journal Article · Sun Nov 01 00:00:00 EDT 2015 · Experimental Cell Research · OSTI ID:1224661

Chiang, Ming-Chang; Cheng, Yi-Chuan; Nicol, Christopher J.; +4 more

Title: Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

Citation Formats

References (37)

Similar Records

Related Subjects